A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

被引：2

作者：

Mazza, Irit Avivi ^{[1
,2
]}

Barba, Pere ^{[3
]}

Yuda, Junichiro ^{[4
]}

Palomba, Maria Lia ^{[5
]}

Alderuccio, Juan Pablo ^{[6
]}

de Vriendt, Ciel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Lim, Francesca Lorraine Wei Inng ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Jain, Nitin ^{[12
]}

Leonard, Jessica T. ^{[13
]}

Coulson, Michelle ^{[14
]}

Hassounah, Nadia ^{[14
]}

Yang, Xiaoling ^{[14
]}

Lu, Haihui ^{[14
]}

Lewandowski, Andrew ^{[14
]}

Polli, Joseph Ryan ^{[14
]}

Klopfenstein, Matthieu

Pastore, Alessandro ^{[15
]}

Brisou, Gabriel ^{[16
]}

机构：

[1] Tel Aviv Univ, BMT Unit, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[3] Vall DHebron Inst Oncol VHIO, Hosp Univ Vall DHebron, Deparment Hematol, La Garriga, Spain

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Mem Sloan Kettering Canc Ctr, Cellular Therapy Serv, New York, NY USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[7] Univ Hosp Ghent Univ Ziekenhuis, Ghent, Belgium

[8] Univ Milan, Milan, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[11] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[13] Oregon Hlth & Sci Univ, Dept Med Hematol Oncol, Portland, OR USA

[14] Novartis Inst BioMed Res, Cambridge, MA USA

[15] Novartis Inst BioMed Res, Basel, Switzerland

[16] Inst Paoli Calmettes, Dept Hematol, Marseille, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
Lu, Haihui
Oka, Adwait
Coulson, Michelle
Polli, Joseph Ryan
Aardalen, Kimberly
Ramones, Melissa
Walker, Dana B.
Carrion, Ana
Alexander, Dylan
Klopfenstein, Matthieu
Akiyama, Masaki
Rucci, Francesca
Granda, Brian
Pastore, Alessandro
BLOOD, 2022, 140 : 3148 - 3148
[2] Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
Budde, Elizabeth
Gopal, Ajay K.
Flinn, Ian W.
Nastoupil, Loretta J.
Gordon, Michael S.
Pang, Ching-Fai
Keyt, Bruce
Carroll, Steve
Leabman, Maya
Hernandez, Genevive
Sison, Iris
Chen, Daniel
Godfrey, Wayne
Armand, Philippe
BLOOD, 2020, 136
[3] Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
Tabbara, Nadeem
Gaut, Daria
Oliai, Caspian
Lewis, Tara
de Vos, Sven
LEUKEMIA RESEARCH REPORTS, 2021, 16
[4] Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies
Furqan, Fateeha
Xu, Huiqing
Zurko, Joanna
Fenske, Timothy S.
Johnson, Bryon
Hamadani, Mehdi
Shah, Nirav N.
BLOOD, 2022, 140 : 12690 - 12691
[5] T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Bernd Schlereth
Cornelia Quadt
Torsten Dreier
Peter Kufer
Grit Lorenczewski
Nadja Prang
Christian Brandl
Sandra Lippold
Kathy Cobb
Kathleen Brasky
Eugen Leo
Ralf Bargou
Krishna Murthy
Patrick A. Baeuerle
Cancer Immunology, Immunotherapy, 2006, 55 : 503 - 514
[6] T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Schlereth, B
Quadt, C
Dreier, T
Kufer, P
Lorenczewski, G
Prang, N
Brandl, C
Lippold, S
Cobb, K
Brasky, K
Leo, E
Bargou, R
Murthy, K
Baeuerle, PA
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (05) : 503 - 514
[7] MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study
Forero, Andres
Hamadani, Mehdi
Fanale, Michelle A.
Bello, Celeste M.
Kipps, Thomas J.
Offner, Fritz
Verhoef, Gregor
Federico, Massimo
Gregory, Stephanie A.
Sonet, Anne
Assouline, Sarit
Perez de Oteyza, Jaime
Tomas, Jose Francisco
Cuneo, Antonio
Zhang, Weiya
Goswami, Trishna
Ibrahim, Ramy
Yao, Zhenling
Herbst, Ronald
Cheson, Bruce D.
BLOOD, 2012, 120 (21)
[8] Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Shah, Nirav N.
Johnson, Bryon D.
Schneider, Dina
Zhu, Fenlu
Szabo, Aniko
Keever-Taylor, Carolyn A.
Krueger, Winfried
Worden, Andrew A.
Kadan, Michael J.
Yim, Sharon
Cunningham, Ashley
Hamadani, Mehdi
Fenske, Timothy S.
Dropulic, Boro
Orentas, Rimas
Hari, Parameswaran
NATURE MEDICINE, 2020, 26 (10) : 1569 - +
[9] Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah
Bryon D. Johnson
Dina Schneider
Fenlu Zhu
Aniko Szabo
Carolyn A. Keever-Taylor
Winfried Krueger
Andrew A. Worden
Michael J. Kadan
Sharon Yim
Ashley Cunningham
Mehdi Hamadani
Timothy S. Fenske
Boro Dropulić
Rimas Orentas
Parameswaran Hari
Nature Medicine, 2020, 26 : 1569 - 1575
[10] A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma
Ken Ohmachi
Michinori Ogura
Youko Suehiro
Kiyoshi Ando
Toshiki Uchida
Ilseung Choi
Yoshiaki Ogawa
Miki Kobayashi
Koichi Fukino
Yuki Yokoi
Jun Okamura
International Journal of Hematology, 2019, 109 : 657 - 664

← 1 2 3 4 5 →